In last trading session, Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw 7,203,675 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $3.35 trading at -$3.77 or -52.95% at ring of the bell on the day assigns it a market valuation of $113.63 Million. That closing price of CYCN’s stock is at a discount of -340.9% from its 52-week high price of $14.77 and is indicating a premium of 49.55% from its 52-week low price of $1.69. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 126.4 Million shares which gives us an average trading volume of 266.41 Million if we extend that period to 3-months.
For Cyclerion Therapeutics, Inc. (CYCN), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas none see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.72 in the current quarter.
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) trade information
In the face of being in the red today for losing -52.95%, in the last five days CYCN remained trading in the green while hitting it’s week-highest on Tuesday, Oct 13 when the stock touched $7.19-5 price level, adding 53.41% to its value on the day. Cyclerion Therapeutics, Inc.’s shares saw a change of 23.16% in year-to-date performance and have moved -51.38% in past 5-day. Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) showed a performance of -54.11% in past 30-days. Number of shares sold short was 937.9 Million shares which calculate 3.52 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5 to the stock, which implies a rise of 49.25% to its current value. Analysts have been projecting $5 as a low price target for the stock while placing it at a high target of $5. It follows that stock’s current price would jump +49.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of 49.25% for stock’s current value.
Cyclerion Therapeutics, Inc. (CYCN) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -6.8% while estimates for its earnings growth in next 5 years are of 0%
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s Major holders
Insiders are in possession of 12.58% of company’s total shares while institution are holding 60.42% percent of that, with stock having share float percentage of 69.11%. Investors also watch the number of corporate investors in a company very closely, which is 135 institutions for Cyclerion Therapeutics, Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at CYCN for having 2.74 Million shares of worth $16.22 Million. And as of June 29, 2020, it was holding 8.09% of the company’s outstanding shares.
The second largest institutional holder is EcoR1 Capital, LLC, which was holding about 2.74 Million shares on June 29, 2020. The number of shares represents firm’s hold over 8.08% of outstanding shares, having a total worth of $16.21 Million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 837285 shares of worth $3.2 Million or 2.47% of the total outstanding shares. The later fund manager was in possession of 744.19 Thousand shares on June 29, 2020, making its stake of worth around $4.4 Million in the company or a holder of 2.19% of company’s stock.